Phaseline

Companies › QED Therapeutics, a BridgeBio company

QED Therapeutics, a BridgeBio company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Mar 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Infigratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2AchondroplasiaMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07169279InfigratinibPhase 2AchondroplasiaOtherMar 2030

From the company's SEC filings

Cash and short-term investments of $1.5bn on 2026-09-30; operating cash outflow about $419m a year; runway about 44 months at that burn, to May 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Targets

FGFR3 (1) FGFR1 (1) FGFR4 (1) FGFR2 (1)

Companies with the same targets

Tyra Biosciences Johnson & Johnson (Janssen) AstraZeneca Taiho Oncology Exelixis TransThera Sciences (Nanjing) Hutchmed Eisai Cogent Biosciences Xynomic Pharmaceuticals

Companies built like this

Eloxx Pharmaceuticals Angitia Zynerba Pharmaceuticals Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.